David Houghton, MD
Neurology with Special Qualifications in Child Neurology · New Orleans, LANPI 1942352224
Payments from drug & device makers
Across 285 payments — averaging $2999.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$354K
- Neurocrine Biosciences, Inc.$259K
- UCB SA$184K
- AbbVie$50K
- Teva Pharmaceuticals USA, Inc.$2K
- Bayer$2K
- plus $4K from 26 others
What the payments were for
- Speaking & faculty fees$300%
- Travel & lodging$2,53827%
- Food & beverage$6,20167%
- Education$4935%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 8 | $354,202 |
| Neurocrine Biosciences, Inc. | 30 | $258,612 |
| UCB SA | 12 | $184,321 |
| AbbVie(2 entities) | 79 | $50,364 |
| Teva Pharmaceuticals USA, Inc. | 64 | $1,768 |
| Bayer | 9 | $1,648 |
| Insightec,inc | 6 | $1,457 |
| Amneal Pharmaceuticals LLC | 7 | $527 |
| MDD US Operations, LLC | 13 | $335 |
| Acadia Pharmaceuticals Inc | 8 | $316 |
| Medtronic(2 entities) | 4 | $194 |
| Boston Scientific | 5 | $135 |
| Amgen | 7 | $133 |
| Merz Pharmaceuticals, LLC | 4 | $121 |
| Turing Medical Technologies | 1 | $120 |
| Ipsen Biopharmaceuticals, Inc | 2 | $107 |
| Eisai Inc. | 4 | $73 |
| Neurelis, Inc. | 3 | $68 |
| Adamas Pharmaceuticals, Inc. | 3 | $55 |
| Catalyst Pharmaceuticals, Inc. | 1 | $50 |
| GE HealthCare | 2 | $39 |
| Jazz Pharmaceuticals Inc. | 2 | $34 |
| Acorda Therapeutics, Inc | 2 | $30 |
| AstraZeneca | 1 | $28 |
| Kyowa Kirin, Inc. | 1 | $28 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $28 |
| Imperative Care, Inc | 1 | $27 |
| Sunovion Pharmaceuticals Inc. | 1 | $22 |
| Novartis | 1 | $20 |
| UCB, Inc. | 1 | $18 |
| Lundbeck LLC | 1 | $16 |
| Portola Pharmaceuticals, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$854,908 in reported general payments places this provider in the 95th percentile of 30 neurology with special qualifications in child neurology providers in Louisiana.
See all neurology with special qualifications in child neurology providers in Louisiana →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 111 | $672,077 |
| IngrezzaValbenazine Tosylate | 68 | $538,159 |
| Austedo XrDeutetrabenazine | 32 | $162,312 |
| RytaryCarbidopa/Levodopa | 99 | $123,110 |
| NuplazidPimavanserin Tartrate | 13 | $105,744 |
| GocovriAmantadine Hcl | 22 | $75,204 |
| NourianzIstradefylline | 21 | $43,450 |
| AptiomEslicarbazepine Acetate | 11 | $27,476 |
| Rasagiline Mesylate | 103 | $16,382 |
| BelsomraSuvorexant | 24 | $13,691 |
| OngentysOpicapone | 12 | $12,857 |
| Emgality PenGalcanezumab-Gnlm | 12 | $8,330 |
| Aripiprazole | 33 | $5,306 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 181 | $4,633 |
| Tetrabenazine | 16 | $2,993 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr | $1,768 | $834,388143 claims |
| Neurocrine Biosciences, Inc.Ingrezza, Ongentys | $258,612 | $551,01780 claims |
| Amneal Pharmaceuticals LLCRytary | $527 | $123,11099 claims |
| Acadia Pharmaceuticals IncNuplazid | $316 | $105,74413 claims |
| MDD US Operations, LLCGocovri | $335 | $75,20422 claims |
| Kyowa Kirin, Inc.Nourianz | $28 | $43,45021 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $22 | $27,47611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 30 neurology with special qualifications in child neurology providers in Louisiana.
Other neurology with special qualifications in child neurology in New Orleans
- Jessica GautreauxNew Orleans$218K
- Ann Henderson TiltonNew Orleans$156K
- Joaquin WongNew Orleans$28K
- Allison ConraveyNew Orleans$15K
- Jeremy TolerNew Orleans$9K
- Daniella MillerNew Orleans$8K
- Maria WeimerNew Orleans$6K
- Rashmi RaoNew Orleans$5K
- Kelly AngelleNew Orleans$3K
- Kayla PenceNew Orleans$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.